Sign In | Join Free | My chinalane.org
chinalane.org
Products
Search by Category
Home > Vitamins, Amino Acids and Coenzymes >

Antiepileptic Medicine Pregabalin CAS 148553-50-8 for Neuralgia Treatment

Categories Pharmaceutical Raw Materials
Brand Name: Pregabalin
Model Number: pr-2035
Certification: GMP
Place of Origin: china
MOQ: 1kg
Price: Negotiable
Payment Terms: Western Union, T/T, MoneyGram,
Supply Ability: 10000kg/month
Delivery Time: 3~5 week days after payment
Packaging Details: 25kg/ bag
English Name: Pregabalin
CAS:: 148553-50-8
MF:: C8H17NO2
EINECS:: 604-639-1
Other Name:: Pregabalin and Intermediates;Pregabalin solution
Appearance:: White powder
Application:: New Antiepileptic Medicine
Purity:: >99%
PSA:: 63.32000
LogP:: 1.78240
  • Haven't found right suppliers
  • Our buyer assistants can help you find the most suitable, 100% reliable suppliers from China.
  • And this service is free of charge.
  • we have buyer assistants who speak English, French, Spanish......and we are ready to help you anytime!
  • Submit Buying Request
    • Product Details
    • Company Profile

    Antiepileptic Medicine Pregabalin CAS 148553-50-8 for Neuralgia Treatment

    New Antiepileptic Medicine Pregabalin CAS : 148553-50-8 Treatment Of Neuralgia


    Product Name:Pregabalin
    Synonyms:Pregabalin cas148553-50-8(whatsapp:+8618830163278);Pregabalin SynonyMs 3-(AMinoMethyl)-5-Methyl-hexanoic acid;Pregabalin 3-(Aminomethyl)-5-methyl-hexanoic acid;Pregabalin solution;Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)-;Pregabalin and Intermediates;Pregabaline ada@tuskwei.com whatsapp
    CAS:148553-50-8
    MF:C8H17NO2
    MW:159.23
    EINECS:604-639-1
    Product Categories:Pregabaline ada@tuskwei.com whatsapp;8618031153937;APIs;Miscellaneous Biochemicals;Intermediates & Fine Chemicals;Neurochemicals;Pharmaceuticals;API;Pfizer compounds;LYRICA
    Mol File:148553-50-8.mol
    Pregabalin Structure
    Pregabalin Chemical Properties
    Melting point194-196°C
    alphaD23 +10.52° (c = 1.06 in water)
    Fp9℃
    storage temp.Store at RT
    solubilitydeionized water: ≥10mg/mL
    formwhite powder
    InChIKeyAYXYPKUFHZROOJ-ZETCQYMHSA-N
    CAS DataBase Reference148553-50-8(CAS DataBase Reference)
    Safety Information
    Hazard CodesXn,T,F
    Risk Statements63-48/22-39/23/24/25-23/24/25-11
    Safety Statements22-36/37-45-16-7
    RIDADRUN1230 - class 3 - PG 2 - Methanol, solution
    WGK Germany3
    HS Code29224999
    Hazardous Substances Data148553-50-8(Hazardous Substances Data)
    MSDS Information
    Pregabalin Usage And Synthesis
    DescriptionPregabalin is a second- generation antiepileptic drug (AED) known with the proprietary brand name of Lyrica® (Pfizer, Tadworth) in the UK and USA (Pfizer, New York, NY).
    Generic formulationMHRA/ CHM advice to minimize risk when switching patients with epilepsy between different manufacturers’ products (including generic products):
    • It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific concerns, such as patient anxiety and risk of confusion/ dosing error.
    IndicationsEpilepsy
    Adjunctive therapy of focal seizures with and without secondary generalization.

    Recommendations summarized from NICE (2012)
    • Seizure types—on referral to tertiary care (focal seizures), contraindicated (generalized tonic- clonic seizures, tonic/ atonic seizures, absence seizures, myoclonic seizures).
    • Epilepsy types—on referral to tertiary care (benign epilepsy with centrotemporal spikes, panayiotopoulos syndrome, late- onset childhood occipital epilepsy), contraindicated (absence syndromes, idiopathic generalized epilepsy, juvenile myoclonic epilepsy, Dravet syndrome, Lennox– Gastaut syndrome).

    Psychiatry
    Generalized anxiety disorder.

    Neurology
    Peripheral and central neuropathic pain.
    Dose titration
    • Epilepsy— adjunctive therapy: 25 mg bd for 7 days, to be increased by 50 mg every 7days; usual maintenance 300 mg daily, divided into 2 or 3 doses (max. 600 mg daily, divided into 2 or 3 doses).
    • Generalized anxiety disorder: 150 mg daily, divided into 2 or 3 doses, for 7 days, to be increased by 150 mg every 7 days (max. 600 mg daily, divided into 2 or 3 doses).
    If stopping pregabalin, it is recommended to taper over at least 1 week to avoid abrupt withdrawal.
    Plasma levels monitoringPregabalin pharmacokinetics are linear over the recommended daily dose range; inter- subject pharmacokinetic variability for pregabalin is low (<20%) and multiple dose pharmacokinetics are predictable from single- dose data. Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin.
    Antiepileptic drus and therapeutic drugs for neuropathic painPregabalin is a new antiepileptic drug, having a γ-amino butyric acid structure on its molecular structure, which has anticonvulsant effects, and is successfully developed by the company Pfizer for the treatment of peripheral neuropathic pain, or adjuvant treatment of partial seizures.
    In December 2008, the US Food and Drug Administration (FDA) approved pregabalin (trade name "Lyrica") for the treatment of diabetic peripheral neuropathic pain (DPN) and postherpetic neuralgia (PHN)which are Both the most common neuropathic pains.
    Neuropathic pain is one of the most difficult chronic pain syndromes to treat , dull pain, burning, tingling as the main feature, there are a lot of incentives of neuralgia, diabetes, infections (such as herpes zoster), cancer and AIDS, etc. can cause neurological pain, in Europe about 3% of the population suffer from neuralgia torture.
    The above information is edited by the chemicalbook of Tian Ye.
    Cautions
    1. Patients with conditions that may precipitate encephalopathy.
    2. Patients with severe congestive heart failure.
    Adverse effectsPregabalin can be associated with adverse effects at the level of the nervous system and other systems.
    Interactions
    • Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans, does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce or be subject to pharmacokinetic interactions.
    • Pregabalin may potentiate the effects of lorazepam.
    • In the post- marketing experience, there are reports of respiratory failure and coma in patients taking pregabalin and other central nervous system depressant medicinal products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.
    With alcohol/food
    • There are no specific foods that must be excluded from diet when taking pregabalin.
    • Pregabalin may potentiate the effects of alcohol.
    Special populationsHepatic impairment
    No dose adjustment is required for patients with hepatic impairment.

    Renal impairment
    Reduce maintenance dose according to degree of reduction in creatinine clearance.

    Pregnancy
    • There is no adequate data from the use of pregabalin in pregnant women. The potential risk for reproductive toxicity in humans is unknown. Pregabalin should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.
    • Pregabalin is excreted into human milk. The effect of pregabalin on newborns/ infants is unknown. A case- by- case decision must be made whether to discontinue breast- feeding or to discontinue pregabalin therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
    Behavioural and cognitive effects in patients with epilepsyPregalin is characterized by a good behavioural profile. This AED does not appear to have significant negative effects on mood or behaviour in patients with epilepsy, although depression has been reported in some patients (dose- dependent effects of mild- to- moderate intensity). A potential abuse or misuse of pregabalin has also been reported, with implications in terms of dependence and withdrawal. pregabalin is also associated with limited negative cognitive effects, mainly related to sedation, decreased arousal, decreased attention and concentration (dose- dependent effects of mild- to- moderate intensity).
    Psychiatric usePregabalin has an approved indication and is widely used for the treatment of generalized anxiety disorder. Several randomized, double- blind, placebocontrolled trials found that pregabalin is an effective treatment for patients with generalized anxiety disorder and social anxiety disorder. Possible implications in the treatment of mood disorders and benzodiazepines dependence are emerging. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention.
    Chemical PropertiesOff-White Solid
    UsesS-Enantiomer of Pregabalin. A GABA analogue used as an anticonvulsant. Anxiolytic analgesic used to treat peripheral neuropathic pain and fibromyalgia.
    UsesPregabalin is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade nam
    Quality Antiepileptic Medicine Pregabalin CAS 148553-50-8 for Neuralgia Treatment for sale
    Send your message to this supplier
     
    From:
    To: Hubei Hongcheng Ming Chemical Co., Ltd.
    Subject:
    Message:
    Characters Remaining: (0/3000)
     
    Inquiry Cart 0